We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add GEHC Stock to Your Portfolio Right Now
Read MoreHide Full Article
Key Takeaways
GE HealthCare's backlog rose 12% to $23.7 billion, supporting revenue growth opportunities into 2027.
Pharmaceutical Diagnostics revenue grows, while Flyrcado adoption and the SOFIE deal expand growth potential.
Adjusted EPS rose 25.1% to $1.34, prompting higher 2026 margin and EPS guidance.
GE HealthCare Technologies, Inc. (GEHC - Free Report) is well-positioned for growth in the coming quarters, supported by record backlog and order momentum, continued strength in its Pharmaceutical Diagnostics business and an expanding pipeline of AI-enabled innovations that are expected to support long-term revenue and margin growth.
However, inflationary pressures, tariff-related uncertainty and higher input costs remain key risks that could weigh on profitability and temper margin expansion despite ongoing pricing and cost-mitigation efforts.
This Zacks Rank #2 (Buy) company’s shares have gained 1.5% year to date against the industry’s 14.7% decline. The S&P 500 composite has risen 9.4% over the same time frame.
Image Source: Zacks Investment Research
The renowned provider of medical technology, pharmaceutical diagnostics and digital solutions has a market capitalization of $37.54 billion. The company projects 7.9% growth for the next five years and expects to maintain its strong performance going forward. It delivered a trailing four-quarter average earnings surprise of 3.15%.
Factors Favoring GEHC’s Growth
Strong Order Growth and Record Backlog: GE HealthCare's order momentum and expanding backlog provide a solid foundation for future revenue growth. Organic orders increased 4% in the third quarter, while the trailing 12-month growth rate reached 4.6%. Book-to-bill was 1.03, and backlog increased 12% year over year to $23.7 billion. Demand was particularly strong in Advanced Imaging Solutions, supported by broad-based interest in CT, cardiovascular interventional systems and other imaging platforms. Management also reported a robust pipeline of opportunities and indicated that the fourth-quarter order book is likely to improve sequentially. Converting this backlog into shipments should support revenue growth into 2027.
Pharmaceutical Diagnostics and Flyrcado Boost Growth Opportunity: Pharmaceutical Diagnostics (PDx) remains a key growth driver, with organic revenue increasing 13.8% in the third quarter, supported by contrast media and radiopharmaceuticals. Flyrcado adoption is also progressing, with approximately 680 doses delivered for the week ended Oct. 23. The demand is expanding beyond existing PET customers as some SPECT users are considering transitioning to PET, opening a substantial conversion opportunity. The planned SOFIE Biosciences acquisition should strengthen radiopharmaceutical manufacturing and last-mile distribution, while adding access to the FAPI-74 pipeline. These developments could reinforce PDx's growth trajectory and expand GE HealthCare's participation in precision medicine.
PCS’ Operational Recovery Looks Promising: Patient Care Solutions (PCS) demonstrated a meaningful recovery during the third quarter, with organic revenue growth of 8.8%, following supplier-related constraints in the first half. Improved product fulfillment, stronger factory execution and better supplier coordination helped the business convert its backlog into sales. Segment EBIT margin also expanded 480 basis points (bps) year over year, reflecting higher volumes and cost productivity. Management expects operational improvements to continue as the business adopts more rigorous daily management and demand-capacity planning. The recovery in PCS is important because sustained improvement in fulfillment could unlock additional revenue from its existing backlog and strengthen the segment's contribution to group profitability.
New Product Innovation and Margin Expansion: GE HealthCare's innovation pipeline is creating opportunities for differentiated growth and improved profitability. The company received CE marking for its Photonova Spectra photon-counting CT system, while its StarGuide GX SPECT/CT platform is awaiting FDA clearance. New ultrasound launches across cardiovascular, women's health and general imaging further broaden its portfolio. These innovations complement strong third-quarter operational execution as adjusted EBIT margin expanded 180 bps to 16.6% and adjusted EPS increased 25.1% to $1.34. Management raised its full-year adjusted EBIT margin outlook to 15.5–15.7% and EPS guidance to $4.95–$5.05, reflecting confidence in sustained operating improvements.
Factors That May Hurt GEHC
Persistent Component Inflation: Despite strong margin improvement in the third quarter, GE HealthCare continues to face inflationary pressure across its supply chain. Higher memory-chip costs and elevated oil prices negatively impacted margins during the quarter, partially offsetting the benefits of volume growth, pricing actions and lower tariff expenses. Management expects inflation and tariffs to persist into 2027, creating uncertainty around the pace of further margin expansion. Although the company has entered multiyear agreements with technology partners to secure memory-chip supplies, it acknowledged that locking in fixed prices may not be realistic. Sustained component-cost inflation could therefore limit the benefits of operational productivity initiatives.
China's Recovery Remains Uncertain: Although GE HealthCare returned to growth in China during the third quarter, the recovery remains fragile. Management reported 7% regional growth, but noted that most of the increase was driven by foreign exchange, while underlying market activity is still improving gradually. The company also acknowledged that volume-based procurement is expanding, potentially intensifying pricing pressure and competition in the region. GE HealthCare is adapting its product configurations and commercial approach to address these market dynamics, but management cautioned that significant work remains to strengthen growth. Continued procurement-related pricing pressure could limit revenue and margin improvement in an important healthcare market.
GE HealthCare Technologies Inc. Price and Consensus
GEHC is witnessing a positive estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has moved up 12 cents to $5.02 per share.
The Zacks Consensus Estimate for fourth-quarter 2026 revenues is pegged at $5.93 billion, indicating a 4.1% rise from the year-ago quarter’s reported number. The consensus mark for EPS is pinned at $1.55, implying an increase of 7.6% year over year.
Other Key Picks
Some other top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, with the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank of 2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 18.6%.
Image: Bigstock
Here's Why You Should Add GEHC Stock to Your Portfolio Right Now
Key Takeaways
GE HealthCare Technologies, Inc. (GEHC - Free Report) is well-positioned for growth in the coming quarters, supported by record backlog and order momentum, continued strength in its Pharmaceutical Diagnostics business and an expanding pipeline of AI-enabled innovations that are expected to support long-term revenue and margin growth.
However, inflationary pressures, tariff-related uncertainty and higher input costs remain key risks that could weigh on profitability and temper margin expansion despite ongoing pricing and cost-mitigation efforts.
This Zacks Rank #2 (Buy) company’s shares have gained 1.5% year to date against the industry’s 14.7% decline. The S&P 500 composite has risen 9.4% over the same time frame.
Image Source: Zacks Investment Research
The renowned provider of medical technology, pharmaceutical diagnostics and digital solutions has a market capitalization of $37.54 billion. The company projects 7.9% growth for the next five years and expects to maintain its strong performance going forward. It delivered a trailing four-quarter average earnings surprise of 3.15%.
Factors Favoring GEHC’s Growth
Strong Order Growth and Record Backlog: GE HealthCare's order momentum and expanding backlog provide a solid foundation for future revenue growth. Organic orders increased 4% in the third quarter, while the trailing 12-month growth rate reached 4.6%. Book-to-bill was 1.03, and backlog increased 12% year over year to $23.7 billion. Demand was particularly strong in Advanced Imaging Solutions, supported by broad-based interest in CT, cardiovascular interventional systems and other imaging platforms. Management also reported a robust pipeline of opportunities and indicated that the fourth-quarter order book is likely to improve sequentially. Converting this backlog into shipments should support revenue growth into 2027.
Pharmaceutical Diagnostics and Flyrcado Boost Growth Opportunity: Pharmaceutical Diagnostics (PDx) remains a key growth driver, with organic revenue increasing 13.8% in the third quarter, supported by contrast media and radiopharmaceuticals. Flyrcado adoption is also progressing, with approximately 680 doses delivered for the week ended Oct. 23. The demand is expanding beyond existing PET customers as some SPECT users are considering transitioning to PET, opening a substantial conversion opportunity. The planned SOFIE Biosciences acquisition should strengthen radiopharmaceutical manufacturing and last-mile distribution, while adding access to the FAPI-74 pipeline. These developments could reinforce PDx's growth trajectory and expand GE HealthCare's participation in precision medicine.
PCS’ Operational Recovery Looks Promising: Patient Care Solutions (PCS) demonstrated a meaningful recovery during the third quarter, with organic revenue growth of 8.8%, following supplier-related constraints in the first half. Improved product fulfillment, stronger factory execution and better supplier coordination helped the business convert its backlog into sales. Segment EBIT margin also expanded 480 basis points (bps) year over year, reflecting higher volumes and cost productivity. Management expects operational improvements to continue as the business adopts more rigorous daily management and demand-capacity planning. The recovery in PCS is important because sustained improvement in fulfillment could unlock additional revenue from its existing backlog and strengthen the segment's contribution to group profitability.
New Product Innovation and Margin Expansion: GE HealthCare's innovation pipeline is creating opportunities for differentiated growth and improved profitability. The company received CE marking for its Photonova Spectra photon-counting CT system, while its StarGuide GX SPECT/CT platform is awaiting FDA clearance. New ultrasound launches across cardiovascular, women's health and general imaging further broaden its portfolio. These innovations complement strong third-quarter operational execution as adjusted EBIT margin expanded 180 bps to 16.6% and adjusted EPS increased 25.1% to $1.34. Management raised its full-year adjusted EBIT margin outlook to 15.5–15.7% and EPS guidance to $4.95–$5.05, reflecting confidence in sustained operating improvements.
Factors That May Hurt GEHC
Persistent Component Inflation: Despite strong margin improvement in the third quarter, GE HealthCare continues to face inflationary pressure across its supply chain. Higher memory-chip costs and elevated oil prices negatively impacted margins during the quarter, partially offsetting the benefits of volume growth, pricing actions and lower tariff expenses. Management expects inflation and tariffs to persist into 2027, creating uncertainty around the pace of further margin expansion. Although the company has entered multiyear agreements with technology partners to secure memory-chip supplies, it acknowledged that locking in fixed prices may not be realistic. Sustained component-cost inflation could therefore limit the benefits of operational productivity initiatives.
China's Recovery Remains Uncertain: Although GE HealthCare returned to growth in China during the third quarter, the recovery remains fragile. Management reported 7% regional growth, but noted that most of the increase was driven by foreign exchange, while underlying market activity is still improving gradually. The company also acknowledged that volume-based procurement is expanding, potentially intensifying pricing pressure and competition in the region. GE HealthCare is adapting its product configurations and commercial approach to address these market dynamics, but management cautioned that significant work remains to strengthen growth. Continued procurement-related pricing pressure could limit revenue and margin improvement in an important healthcare market.
GE HealthCare Technologies Inc. Price and Consensus
GE HealthCare Technologies Inc. price-consensus-chart | GE HealthCare Technologies Inc. Quote
GEHC Estimate Trend
GEHC is witnessing a positive estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has moved up 12 cents to $5.02 per share.
The Zacks Consensus Estimate for fourth-quarter 2026 revenues is pegged at $5.93 billion, indicating a 4.1% rise from the year-ago quarter’s reported number. The consensus mark for EPS is pinned at $1.55, implying an increase of 7.6% year over year.
Other Key Picks
Some other top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, with the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank of 2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 18.6%.